The 12 peptides removed from FDA restriction in 2026: what each one does
A short reference for the 12 peptides FDA removed from Category 2 on April 22, 2026.
TL;DR
- FDA removed 12 peptides from Category 2 on April 22, 2026, after their nominations were withdrawn.
- Removal from Category 2 did not put them in Category 1 or on the 503A bulks list. Compounded products are not FDA-approved.
- FDA's advisory committee voted on seven of the 12 in July 2026. As of September 14, 2026, FDA has not made a final decision.
What it is
In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. On April 15, 2026, FDA gave notice that 12 peptides would leave Category 2 (in plain English: FDA's list of substances that raise significant safety risks) after seven days, because their nominations were withdrawn. FDA removed them on April 22, 2026 (FDA Bulk Drug Substances Nominations). As of September 14, 2026, they are not in any FDA 503A category and are not on the 503A bulks list. The named peptides span tissue repair, immune signaling, sleep, and longevity research. Law firms say removal from Category 2 does not, by itself, put a substance on the bulks list or in Category 1.
How it works
Think of FDA categories as labels on different shelves in a storeroom. Category 1 is the "under evaluation" shelf. FDA's interim policy of not taking action against compounding with a substance not yet on the 503A bulks list applies only to Category 1 substances, when other conditions are met. Category 2 sits behind a locked door — FDA says those substances raise significant safety risks. The April 2026 change took 12 peptides out from behind the locked door. It did not put them on the Category 1 shelf or on the bulks list. FDA's July 2026 advisory committee slides say FDA is evaluating these substances at its discretion. The shelf labels do not say anything about whether the compounded product is FDA-approved (it is not).
Who asks about it
People come to this question after seeing news headlines about peptide "reclassification" or "legalization" and want a concrete list. The honest answer: the April 22, 2026 list change is real, the February 2026 podcast remark was not a formal action, and the change concerns FDA's compounding categories — not FDA approval of the finished compounded product.
What the research says
The 12 peptides FDA removed from Category 2 on April 22, 2026 include BPC-157 (tissue and gut repair research), TB-500 / thymosin beta-4 (tissue repair), KPV (alpha-MSH fragment with anti-inflammatory research), MOTS-c (mitochondria-derived peptide with metabolic research), DSIP (delta sleep-inducing peptide), epitalon (telomere-related research), and Semax (cognitive-function research). The other five are cathelicidin LL-37, dihexa acetate, GHK-Cu (injectable routes), PEG-MGF, and melanotan II. Selank (anxiolytic research) is often named with this group, but FDA removed Selank from Category 2 earlier, on September 27, 2024. Each compound has its own published research base — some thin, some decades-deep — and reclassification does not change that evidence base.
What to know before considering it
Removal from Category 2 changes a peptide's FDA list status. It does not change the underlying research, dose responsibility, or the requirement for a licensed physician evaluation. Patients reading reclassification news should not assume "available now" or "FDA-approved." Removal from Category 2 does not, by itself, put a substance on the 503A bulks list or in Category 1.
The Halftime POV
The reclassification news is real and meaningful — FDA removed 12 peptides from Category 2. It is not, by itself, an endorsement of any specific peptide for any specific use. The honest read is: a real list change, same homework on the science.
Related reading:
- Category 1 vs Category 2 peptides: the access framework
- Secretary Kennedy's February 2026 peptide remarks
- What the April 2026 FDA peptide reclassification path actually means
FAQ
Q: Which peptides were reclassified in 2026? A: FDA removed 12 peptides from Category 2 on April 22, 2026, after their nominations were withdrawn: BPC-157, cathelicidin LL-37, dihexa acetate, emideltide (DSIP), Epitalon, GHK-Cu (injectable routes), KPV, PEG-MGF, melanotan II, MOTS-c, Semax, and TB-500. As of September 14, 2026, they are not in any FDA 503A category and are not on the 503A bulks list. Non-injectable GHK-Cu is in Category 1. Selank is often named with this group, but FDA removed Selank from Category 2 earlier, on September 27, 2024.
Q: Does reclassification mean these are FDA-approved? A: No. Removal from Category 2 did not put these peptides in Category 1 or on the 503A bulks list. It also does not mean that any compounded product is FDA-approved.
Q: When will the reclassified peptides be available? A: FDA's list change took effect on April 22, 2026, but it did not put these peptides on the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the Section 503A bulk drug substances list. It voted against emideltide (DSIP). The committee is advisory. As of September 14, 2026, FDA has not made a final decision.
Disclaimer
Several peptides discussed in this article — including KPV, MOTS-c, DSIP, epitalon, Selank, and Semax — were previously in FDA's Category 2. FDA removed them from Category 2 (September 2024 or April 2026, depending on the peptide). As of September 14, 2026, they are not in any FDA 503A category and are not on the 503A bulks list. As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
Which peptides were reclassified in 2026?
FDA removed 12 peptides from Category 2 on April 22, 2026, after their nominations were withdrawn: BPC-157, cathelicidin LL-37, dihexa acetate, emideltide (DSIP), Epitalon, GHK-Cu (injectable routes), KPV, PEG-MGF, melanotan II, MOTS-c, Semax, and TB-500. As of September 14, 2026, they are not in any FDA 503A category and are not on the 503A bulks list. Non-injectable GHK-Cu is in Category 1. Selank is often named with this group, but FDA removed Selank from Category 2 earlier, on September 27, 2024.
Does reclassification mean these are FDA-approved?
No. Removal from Category 2 did not put these peptides in Category 1 or on the 503A bulks list. It also does not mean that any compounded product is FDA-approved.
When will the reclassified peptides be available?
FDA's list change took effect on April 22, 2026, but it did not put these peptides on the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the Section 503A bulk drug substances list. It voted against emideltide (DSIP). The committee is advisory. As of September 14, 2026, FDA has not made a final decision.
Keep reading
Every protocol is reviewed by a licensed physician and filled by a licensed 503A compounding pharmacy.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.